---
title: Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive
  High-Risk Myelodysplastic Syndromes
date: '2024-12-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39652823/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241209184155&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'Patients with higher-risk myelodysplastic syndromes (HR MDS) have a
  median survival of ~1.5 years with azacitidine, and hematopoietic stem cell transplantation
  is their only curative option. Therefore, improved therapies are needed. This phase
  1b study investigated safety and efficacy of venetoclax, a selective BCL-2 inhibitor,
  at the recommended phase 2 dose (RP2D: 400 mg for 14 days/28-day cycle), in combination
  with azacitidine (75 mg/m2 for 7 days/28-day cycle) for treatment-naive HR ...'
disable_comments: true
---
Patients with higher-risk myelodysplastic syndromes (HR MDS) have a median survival of ~1.5 years with azacitidine, and hematopoietic stem cell transplantation is their only curative option. Therefore, improved therapies are needed. This phase 1b study investigated safety and efficacy of venetoclax, a selective BCL-2 inhibitor, at the recommended phase 2 dose (RP2D: 400 mg for 14 days/28-day cycle), in combination with azacitidine (75 mg/m2 for 7 days/28-day cycle) for treatment-naive HR ...